covid-19 
Fierce Pharma
MARCH 25, 2024
officials are pressing the company to pay royalties linked to the commercialization of its lucrative Pfizer-partnered COVID-19 vaccine. . | Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S.
Fierce Pharma
JUNE 12, 2023
Two years after the initial COVID-19 vaccine push swept across the globe, Pfizer’s COVID-19 vaccine partner BioNTech is heading to court in its home country of Germany to defend itself against alle | The drugmaker will defend itself against claims from a German healthcare worker who sued the company for at least 150,000 euros ($161,500).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
APRIL 19, 2023
Goodbye, original COVID-19 vaccines: FDA updates shot guidance, pulls monovalent authorizations zbecker Wed, 04/19/2023 - 11:04
Fierce Pharma
OCTOBER 26, 2023
but Merck’s COVID-19 pill Lagevrio somehow remains a force. but Merck’s COVID-19 pill Lagevrio somehow remains a force. It’s been grounded in Europe and reduced to irrelevancy in the U.S., It’s been grounded in Europe and reduced to irrelevancy in the U.S.,
Advertiser: ZoomInfo
More than two years into the pandemic, COVID-19 is far from over. Businesses are tasked with beating pre-pandemic numbers, making marketing more essential than ever before.
World of DTC Marketing
APRIL 11, 2021
QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Both Pfizer and Moderna stand to make billions, and even though J&J said they would not make money on the first batch, they are already positioning yearly Covid Vaccine shots that could net them billions in sales.
Fierce Pharma
AUGUST 28, 2023
As Alnylam persists in its COVID-19 patent litigation, the RNAi specialist has been dealt a blow in one of its lawsuits against Moderna. | As Alnylam persists in its COVID-19 patent litigation, the RNAi specialist has been dealt a blow in one of its lawsuits against Moderna.
Advertiser: ZoomInfo
According to Harvard Business Review, the COVID-19 pandemic exacerbated seismic shifts that were already rocking the talent market. That means placing the right people in the right roles can be the difference between your business growing or stagnating — and the competition is getting fierce.
Advertiser: ZoomInfo
The economic disruption of the COVID-19 pandemic has caused some active candidates to be more cautious. As the New York Times observed, “It’s a weird moment for the American economy.” And recruiting professionals are caught in the middle. Businesses are looking to hire quickly, but they face a disjointed market.
Advertiser: ZoomInfo
Businesses are laying off workers, shutting their doors (some permanently), and struggling to react to the radical destruction that coronavirus (COVID-19) is doing to our society and communities. Most have already sustained massive damage, and we still have yet to see the scope of this global pandemic.
Expert insights. Personalized for you.
353 
Let's personalize your content